The FDA approved Siponimod for the treatment of relapsing forms of MS

The FDA recently approved the use of Siponimod for the treatment of relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease (SPMS).

Read full article ↗